Oklo Clears Its Biggest Safety Hurdle Yet — But Can a Test Reactor Justify a $9 Billion Valuation?

Shares of Oklo surged 6.5% to $55.88 after the U.S. Department of Energy gave the green light on the company's final safety report for its Groves test reactor in Texas — the last major paperwork milestone before the facility can begin loading nuclear fuel. A same-day Buy reiteration from B. Riley, carrying a $92 price target, amplified the rally. The question now: does clearing a bureaucratic checkpoint bring real value, or just excitement, to a company with no revenue?

• A First-of-Its-Kind Approval Puts Oklo Ahead of Peers. Groves is the first advanced reactor project to receive this final safety approval on privately owned land, using entirely commercially sourced fuel and equipment.

With this and the earlier preliminary safety review both cleared, only a DOE readiness review and startup authorization remain before fuel loading.

Oklo is targeting first criticality — the moment a reactor sustains its own chain reaction — this month. Meeting that deadline would be a tangible proof point for a company that has sold investors on promises, not power.

• The Isotope Business Is the Near-Term Revenue Story. The Groves facility supports Oklo's isotope business, aiming to establish domestic production of critical isotopes used in cancer diagnosis, advanced manufacturing, space exploration, and national security.

Many of these isotopes are currently sourced from overseas suppliers or produced in aging facilities. If Oklo can produce them domestically at scale, it opens a revenue stream years before its larger Aurora power reactors come online — which Goldman Sachs pegs at 2028 at the earliest.

• Wall Street Is Split, and the Cash Burn Is Real. Analyst price targets range wildly from $14 to $140, reflecting deep uncertainty about commercialization timelines.

Oklo still generates zero commercial revenue.

The company guided 2026 operating cash use of $80M–$100M and investing cash use of $350M–$450M, though it holds roughly $2.5 billion in cash with no debt, giving it a long runway.

• B. Riley's Endorsement Matters, But It's One Voice. Analyst Ryan Pfingst at B. Riley is rated the most accurate analyst covering Oklo, with a 71% success rate and ranking #386 among over 12,000 tracked analysts.

Still, Wall Street's overall consensus is only a moderate Buy — 10 Buys versus six Holds. At $55.88, the stock sits well below the $82.78 average target, suggesting upside — but only if milestones keep falling on schedule.